Repligen (RGEN) Reports In-Line Q4 EPS, Offers Guidance

Repligen (NASDAQ: RGEN) reported Q4 EPS of $0.21, in-line with the analyst estimate of $0.21. Revenue for the quarter came in at $51.9 million versus the consensus estimate of $50.4 million.

GUIDANCE:

Repligen sees FY2019 EPS of $0.81-$0.86, versus the consensus of $0.85. Repligen sees FY2019 revenue of $218-225 million, versus the consensus of $217.25 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 6c
• Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c